Abstract
Chris Boshoff, Senior Vice President of Immuno-Oncology, Translational and Early Development at Pfizer, and colleagues Samra Turajlic and Charles Swanton from the Francis Crick Institute and University College London give us their personal point of view on new insights and future therapeutic approaches for renal cancer.
© 2018 Pfizer Inc.
MeSH terms
-
Carcinoma, Renal Cell* / classification
-
Carcinoma, Renal Cell* / diagnosis
-
Carcinoma, Renal Cell* / mortality
-
Carcinoma, Renal Cell* / pathology
-
Humans
-
Kidney Neoplasms* / classification
-
Kidney Neoplasms* / diagnosis
-
Kidney Neoplasms* / mortality
-
Kidney Neoplasms* / pathology
-
Kidney Tubules, Proximal / pathology
-
Prognosis